

QIBA PET-Amyloid Biomarker Committee

Friday, May 20, 2022, at 9 AM CT

Call Summary

In attendance:

Anne M. Smith, PhD (Co-chair)

Dawn Matthews, MS, MBA (co-chair)

Peter Ngum, MSc

Nancy Obuchowski, PhD

Jean-Luc Vanderheyden, PhD

Richard Wahl, MD, FACR

RSNA

Joe Koudelik

Julie Lisiecki

Moderator: Dr. Smith

VOTE PASSED: NM Coordinating Committee (CC) Ballot

- The NM CC vote-to-publish the revised Profile as Technically Confirmed (Stage 3) was successful.
- The ballot closed at EOB on Thursday, May 19 with a majority (9 votes) in favor to release the Profile (N=14), with 1 abstention and 1 “no” vote (minor text edits to be addressed by BC leaders prior to wiki posting).
- The clean version of the Profile and Checklist will need to be posted to the [Profiles QIBA Wiki page](#).
- [Dashboard](#) was updated accordingly.

The following were discussed:

- Manuscript publication / advertising of the Profile as available for use
- Transition from FDG-PET to Tau BC

Action items

Manuscript

- The revised manuscript must be resubmitted to [The Journal of Nuclear Medicine](#) (JNM) by May 25th
- [Co-authors'](#) disclosures and conflicts of interest (COI) statements are needed for the journal
- [Dr. Smith](#) to aggregate signatures
- [Dr. Obuchowski](#) to provide a graph for the manuscript (3 figures needed)

Amyloid Profile

- [Ms. Matthews](#) to provide a clean copy of the Profile and checklist for wiki posting / link to journal
- In the future, aim to streamline the checklist by eliminating items that are routinely done
- Some pending items remain regarding PET Amyloid outreach; leadership to discuss plan for utilization and engaging new resources to follow up
- Produce an online questionnaire with scoring capability, modeled after FDG-PET BC

Planning for a Tau BC

- PET Amyloid BC to end its activities and transition to PET Tau BC; New Co-chairs and members needed
- Amyloid BC leadership to identify what QIBA would like to accomplish with the Tau Profile in order to help determine scope of the Profile and plan for potential groundwork
- There is more economic impetus for Tau to be used clinically, as local insurance carriers determine payment, and there is no regulatory roadblock as for amyloid
- Potential candidates were identified, and current co-chairs will reach out to them
- [RSNA Staff](#) to invite current PET Amyloid membership to an inaugural call on 7/15 at 9 am CT
- Literature search will be needed to determine if there is sufficient test-retest data
- A [New QIBA Biomarker Committee Application](#) will also be needed

Older Amyloid action items to be addressed - please strike those that are complete

- Following Technical Confirmation:
 - List key highlights for the best opportunities for harmonization: recommendations requested
 - Ms. Matthews and Dr. Foster to schedule a call with Dr. Koeppe to discuss the ADNI-QIBA gap analysis
 - Dr. Wong to be included
 - Ms. Matthews to reach out to Dr. Seibyl regarding introduction to Invicro
 - BC discussion on how to handle resistance to Profile requirements

Next call – July 15th at 9 am CT for PET Tau inaugural / recruitment meeting